The coronavirus vaccine developed by Oxford university and AstraZeneca has shown promising results in the first phase of its clinical trials.
The eagerly awaited study, published in The Lancet on Monday, showed that the AZD1222 vaccine generated “robust immune responses” and was tolerated by
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
